Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Arbutus Biopharma Corporation (NASDAQ: ABUS).

Full DD Report for ABUS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABUS)

Arbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q3 2018 Results - Earnings Call Transcript
Arbutus Biopharma Corp (ABUS) Q3 2018 Earnings Conference Call November 7, 2018 04:30 pm ET Executives Pam Murphy - IR Mark Murray - President and CEO Mike Sofia - CSO David Hastings - CFO Analysts Liisa Bayko - JMP Securities Katherine Xu - William Blair Keay Nakae -...
Source: SeekingAlpha
Date: November, 07 2018 20:41
Arbutus Biopharma misses by $0.08
Arbutus Biopharma (NASDAQ: ABUS ): Q3 GAAP EPS of -$0.49 misses by $0.08 . Revenue of $1.6M (-76.8% Y/Y) Press Release More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 07 2018 16:04
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus ...
Source: GlobeNewswire
Date: November, 07 2018 16:01
Arbutus to Report Third Quarter 2018 Financial Results
WARMINSTER, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, N...
Source: GlobeNewswire
Date: October, 31 2018 08:30
Arbutus Names New Members to its Board of Directors
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle Potter have been appointed to the Arbutus Board of Directors, effective Oc...
Source: GlobeNewswire
Date: October, 22 2018 08:30
Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?
Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi...
Source: SeekingAlpha
Date: October, 19 2018 11:23
New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Arbutus Biopharma Corporation (NASDAQ:ABUS), Tata Motors Ltd (NYSE:TTM...
Source: GlobeNewswire
Date: October, 19 2018 08:25
Premarket analyst action - healthcare
Argenx (NASDAQ: ARGX ) initiated with Outperform rating and $110 (51% upside) price target at Evercore ISI. More news on: Argenx SE, Elanco, KalVista Pharmaceticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: October, 15 2018 07:30
Weekly market movement wrap
See a week over week comparison below for the following indices, equities, commodities, bonds and currencies. More news on: Youngevity International, Inc., CorMedix Inc., Pyxus International, Inc., Top stock market news, Quick stock ideas, News on the U.S. economy, Financial stocks news, H...
Source: SeekingAlpha
Date: October, 13 2018 17:35
Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial Average declined 0.21 percent to close at 26,430.57, while the S&P 500 Index decr...
Source: ACCESSWIRE IA
Date: October, 10 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-124.484.6154.624.40133,595
2018-12-114.544.424.554.3977,923
2018-12-104.394.444.544.31218,405
2018-12-074.604.414.664.3768,848
2018-12-064.454.544.674.4463,133

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1222,30537,52959.4340Short
2018-12-1124,23529,69581.6131Short
2018-12-1041,13582,07850.1170Short
2018-12-0712,37730,19540.9902Short
2018-12-063,74212,24530.5594Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABUS.


About Arbutus Biopharma Corporation (NASDAQ: ABUS)

Logo for Arbutus Biopharma Corporation (NASDAQ: ABUS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ABUS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 23 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 12 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: March, 16 2018

       

       


      Daily Technical Chart for (NASDAQ: ABUS)

      Daily Technical Chart for (NASDAQ: ABUS)


      Stay tuned for daily updates and more on (NASDAQ: ABUS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ABUS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ABUS and does not buy, sell, or trade any shares of ABUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/